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Human  and  rat  hepatic  tissue  express  many  serotonin  (5-HT)  receptor  subtypes,  such  as  5-HT1B, 5-
HT2A,  5-HT2B and  5-HT7 receptors,  which  mediate  diverse  effects.  5-HT  is known  to regulate  several
key  aspects  of liver  biology  including  hepatic  blood  ﬂow,  innervations  and  wound  healing.  5-HT  is also
known  to  enhance  net  glucose  uptake  during  glucose  infusion  in fasted  dogs,  but  little  is known  about
the  ability  of  5-HT  to  control  hepatic  glucose  metabolism,  especially  glycolysis.  This  study  addresses
the  potential  of  5-HT  to  regulate  PFK  activity  and  the  mechanisms  related  to the  enzyme  activity.
Based  on our  results,  we  are  the  ﬁrst  to provide  evidence  that  5-HT  up-regulates  PFK  in mouse  hep-
atic  tissue.  Activation  of  the  enzyme  occurs  through  the  5-HT2A receptor  and  phospholipase  C (PLC),
resulting  in  PFK  intracellular  redistribution  and  favoring  PFK  association  to the  cytoskeletal  f-actin-egulation
etabolism
etabolom
enriched  fractions.  Interestingly,  5-HT  and  insulin  act in  a synergistic  manner,  likely  because  of  the
ability  of insulin  to  increase  fructose-2,6-bisphosphate  because  the  presence  of this  PFK  allosteric  reg-
ulator enhances  the  5-HT  effect  on  the  enzyme  activity.  Together,  these  data  demonstrate  the  ability
of  5-HT  to  control  hepatic  glycolysis  and  present  clues  about  the mechanisms  involved  in  these  pro-
cesses,  which  may  be  important  in  understanding  the  action  of  5-HT during  the  hepatic  wound  healing
process.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license.. Introduction
Serotonin (5-hydroxytryptamine; 5-HT1) is a biogenic amine
hat functions as a ligand for a large family of 5-HT receptors (Hoyer
t al., 1994). Enterochromafﬁn cells of the gastrointestinal tract are
esponsible for the synthesis of 90% of the total 5-HT in the body
Ruddell et al., 2008). Serotonin is an important neurotransmit-
er within the central nervous system (CNS) and the autonomic
ervous system (ANS), where the systems controlled by 5-HT are
etermined by the variable expression pattern of 5-HT receptors
ithin the CNS and ANS (Hoyer et al., 1994). In the CNS, serotonin
s known to control mood, behavior, learning, sleep and anxiety
Abbreviations: 5-HT, serotonin; 5-HT2A, subtype 2A of the serotonin recep-
or;  PI3K, phosphatidylinositol 3 kinase; PFK, 6-phosphofructo-1-kinase; F6P,
ructose-6-phosphate; F1,6BP, fructose-1,6-bisphosphate; F2,6BP, fructose-2,6-
isphosphate; PKC, protein kinase C; PLC, phospholipase C.
∗ Corresponding author at: Laboratório de Enzimologia e Controle do
etabolismo (LabECoM), Departamento de Fármacos, Faculdade de Farmácia, Uni-
ersidade Federal do Rio de Janeiro, Ilha do Fundão, Rio de Janeiro RJ, 21941-590,
razil. Tel.: +55 21 2560 8438; fax: +55 21 2560 8438.
E-mail address: maurosp@ufrj.br (M.  Sola-Penna).
357-2725 © 2011 Elsevier Ltd.   
oi:10.1016/j.biocel.2011.10.010
Open access under the Elsevier OA license.(Leysen, 2004; Harvey et al., 2004). Peripherally, serotonin is able
to mediate vascular contraction and relaxation, gastrointestinal
motility, cell proliferation, apoptosis and platelet aggregation (Roth
et al., 1998).
Human hepatic metabolic functions are known to be regulated
by both sympathetic (Cruise et al., 1987) and parasympathetic
(Kato and Shimazu, 1983) branches of the ANS. Serotonergic nerve
ﬁbers are part of the peptidergic family of the ANS, localized in
the tunica media on branches of the hepatic artery, portal vein,
bile ducts and the connective tissue of the interlobular septa from
humans (el-Salhy et al., 1993) and rats (Stoyanova, 2004). Sero-
tonin presents the ability to elicit portal resistance and thereby
regulate portal vein pressure (Richardson and Withrington, 1977;
Cummings et al., 1986). The effects of serotonin on isolated mesen-
teric veins are blocked by ketanserin, a known 5-HT2A antagonist,
suggesting the involvement of the 5-HT2A receptor (Cummings
et al., 1986). The hepatic stellate cell (HSC) system, which is pro-
posed to regulate hepatic blood ﬂow, undergoes activation and
acquires a smooth muscle cell-like phenotype with enhanced
contractile capabilities in response to liver injury, has been demon-
strated to express functional 5-HT2A and 5-HT2B receptors (Ruddell
et al., 2006). Sinusoidal endothelial cells (SECs) also respond to a
 of Bio
5
1
t
5
i
d
t
e
m
2
F
a
e
a
s
s
e
r
t
e
m
d
h
P
w
b
a
o
i
g
m
e
l
t
k
i
c
a
s
t
u
h
c
i
c
6
f
r
a
m
2
2
b
m
U
f
E
tW.S. Coelho et al. / The International Journal
-HT-mediated stimulus (Brauneis et al., 1992, Gatmaitan et al.,
996), which induces the activation of the myosin light chain
hrough rapid inﬂux of extracellular Ca2+ (Gatmaitan et al., 1996).
-HT also inhibits cAMP synthesis and activates phospholipase A2
n these cells (Gatmaitan et al., 1996). In fact, many studies have
emonstrated the responsiveness of the human hepatic vascula-
ure to serotonin and ketanserin (Hadengue et al., 1987, 1989; Islam
t al., 2000; Vorobioff et al., 1989), where serotonin plays a role pro-
oting the contraction of the human hepatic artery (Islam et al.,
000).
The liver demonstrates a remarkable capacity for regeneration.
ollowing a 70% partial hepatectomy (PHx), rodents are able to
lmost completely restore the lost mass within 14 days (Mabuchi
t al., 2004). The process of wound healing is tightly regulated
nd is known to involve many hepatic and extra-hepatic tis-
ues. In addition, recent studies highlighting the importance of
erotonin in rodent hepatic wound healing after injury (Kulinskii
t al., 1983a,b,c)  led to increased interest in understanding the
ole of 5-HT in hepatic regeneration. It has been shown that sero-
onin elevates cAMP and cGMP within rat hepatocytes (Aslamova
t al., 1985) and enhances hepatic poly-(A) RNA synthesis in nor-
al  healthy Wistar rats (Roy et al., 1985). Ketanserin has been
emonstrated to be a potent inhibitor of liver regeneration and
epatocyte proliferation following PHx (Papadimas et al., 2006).
latelets have been identiﬁed as the major source of serotonin,
hich drives liver regeneration in a process that is mimicked
y the 5-HT2 agonist 2,5-dimethoxy-4-iodoamphetamine (DOI)
nd antagonized by ketanserin (Lesurtel et al., 2006). Again, these
bservations suggest a key role for the 5-HT2 family of receptors
n mediating hepatic regeneration, likely through 5-HT mito-
enic effects (Lesurtel et al., 2006; Hsu, 1995). However, the
echanisms underlying these observations are yet to be fully
xplored.
Serotonin acts within the liver, on the vessels supplying the
iver with blood, and within the serotonergic nerve connections
hat regulate liver function (Ruddell et al., 2008). However, little is
nown about the actions of serotonin on carbohydrate metabolism
n the liver. Moore and colleagues (Moore et al., 2004a,b, 2005b)
onducted a series of studies and demonstrated enhanced hep-
tic glucose uptake after portal infusion of 5-HT or inhibitors of
erotonin uptake. They further reported that ﬂuvoxamine, a selec-
ive serotonin reuptake inhibitor, increases net hepatic glucose
ptake, enhancing hepatic glycogen storage under condition of
yperglycemia and hyperinsulinemia, but not under euinsulinemic
onditions (Moore et al., 2005a).  Nevertheless, there have no stud-
es that investigated the effects of serotonin upon hepatic glycolysis
ontrol.
In this study, we demonstrate that 5-HT up-regulates
-phosphofructo-1-kinase (PFK; phosphofructokinase; ATP:d-
ructose-6-phosphate-1-phosphotransferase; EC 2.7. 1.11), the
ate-limiting enzyme of glycolysis, through the 5-HT2A receptor by
ltering the enzyme cellular localization in an insulin synergistic
anner.
. Materials and methods
.1. Materials
ATP, fructose-6-phosphate, ketanserin tartrate salt, fructose 2,6
isphosphate (F-2,6-BP), insulin, serotonin, genistein, and wort-
annin were purchased from Sigma Chemical St. Louis, MO,  USA.
-73122, phorbol-12-myristate-13-acetate (PMA) was  purchased
rom Calbiochem. 32Pi was obtained from the Instituto de Pesquisas
nerge ticas e Nucleares (SP). [-32P]ATP was prepared according
o (32a).chemistry & Cell Biology 44 (2012) 150– 157 151
2.2. Mouse liver homogenate
Animal experimentation was conducted according to the Ani-
mal  Care Procedures. Male Swiss mice (20–25 g) were fed ad libitum
and killed by cervical dislocation with prompt removal of the liver.
Liver samples were weighed and homogenized for 30 s in a
Polytron (Brinkmann Instruments, Westbury, NY, USA) in the pres-
ence of 6 vol of buffer containing 100 mM Tris–HCl, pH 7.4, 30 mM
KF (potassium ﬂuoride), 4 mM EDTA, 1.5 mM  2-mercaptoethanol
and 250 mM sucrose, 1 mM sodium pyrophosphate (homogeniz-
ing buffer). Homogenized tissues were centrifuged for 10 min  at
100 × g at 4 ◦C to separate cellular debris and non-digested tissues.
The resulting supernatant was  used for all measured parameters.
The protein content measurements were performed according
to (Bradford, 1976), and the total protein concentration used in each
experiment was  50 g/ml.
2.3. Preparation of soluble and bound PFK
Cytoskeleton-bound and soluble PFK were separated as
described previously (El-Bacha et al., 2003; Gomes Alves and Sola-
Penna, 2003). Tissues were homogenized as described above, and
they were centrifuged for 10 min  at 100 × g at 4 ◦C to separate the
cellular debris and the non-digested tissues. The resulting super-
natant, which we named total homogenate (TH), was  centrifuged
for 30 min  at 27,000 × g at 4 ◦C. The resulting low-speed pellet,
P1, is a fraction that is enriched with mitochondria, lysosomes,
and nuclear components. The low-speed supernatant, S1, contain-
ing most of cytoplasmic structures was  centrifuged for 30 min
at 120,000 × g at 4 ◦C. The resulting high-speed supernatant, S2,
retains most of the soluble structures and the high-speed pellet,
P2, contains the microsomal fraction and the cytoskeleton compo-
nents as described previously (El-Bacha et al., 2003; Gomes Alves
and Sola-Penna, 2003). All fractions (TH, S1, P1, S2 and P2) were
assayed for PFK activity and protein concentration.
2.4. Radioassay for PFK activity
PFK activity was measured using the method described by
(Sola-Penna et al., 2002), with the modiﬁcations introduced by
(Zancan and Sola-Penna, 2005a)  in medium containing 50 mM
Tris–HCl (pH 7.4), 5 mM (NH4)2SO4, 5 mM MgCl2, and 1 mM [-
32P]ATP (4 Ci/mol), 1 mM F6P was  added after incubation in
the appropriate conditions and length of time as indicated in the
ﬁgures. The reaction was started with the addition of enough
muscle homogenate to reach a ﬁnal concentration of 100 g pro-
tein/ml. The reaction was  ended by the addition of a suspension
of activated charcoal in 0.1 M HCl and 0.5 M mannitol. In addi-
tion, after centrifugation (10 min, 27,000 × g), the supernatant
containing [1-32P]fructose-1,6-bisphosphate was analyzed in a liq-
uid scintillation counter. Appropriate blanks (samples without
fructose-6-phosphate) were measured, and their values were sub-
tracted from all measurements to account for any ATP hydrolysis.
One unit of PFK was attributed to the formation rate of 1 nmol of
fructose-1,6-bisphophate per minute.
3. Results
Incubation of mouse liver samples with 5-HT results in a signif-
icant upregulation of enzyme activity on TH in a dose-dependent
manner (Fig. 1b). The maximum effect is observed with a dose of
10 M 5-HT. At this dose, PFK activity was  increased 50.13 ± 8.91%
compared to control (p < 0.05, Student’s t-test). We  next incubated
the liver homogenate with 10 M 5-HT for 60 min, and aliquots
were retrieved from the samples throughout the incubation at the
152 W.S. Coelho et al. / The International Journal of Biochemistry & Cell Biology 44 (2012) 150– 157
Fig. 1. The effects of 5-HT on PFK activity in mouse hepatic tissue is time and dose dependent. PFK activity was measured as described in the Section 2. The assay was initiated
by  the addition of hepatic homogenates, which were preincubated with the conditions indicated in the panels, to a ﬁnal concentration of 50 g/ml. The reaction was  ended
after  6 min when the formation of the product was  linear (ﬁrst order kinetics). The data are plotted as mean ± standard error of 4 independent experiments (n = 4). (a) The
presence  of 10 M 5-HT (open circles) up-regulates PFK activity after a 30 min incubation (*p < 0.05 vs. control). (b) The effects of 5-HT are dose-dependent and promote PFK
activation at concentrations between 10 M and 50 M 5-HT (*p < 0.05 vs. control).
Fig. 2. The synergistic effects of 5-HT and F-2,6-BP on PFK activity are shown. Hepatic mouse samples were preincubated for 30 min  in the conditions indicated in the ﬁgures.
PFK  activity was measured as described in the Section 2. The data are plotted as mean ± standard error of 6 independent experiments (n = 6). (a) Simultaneous stimulation
with  10 M 5-HT and 100 nM F-2,6-BP upregulates PFK activity compared to control or the action of either alone. (b) Dose dependent response of 5-HT upon PFK activity in
the  presence of 100 nM F-2,6-BP (*p < 0.05 vs. control; **p < 0.05 vs. 5-HT or F-2,6-BP alone). (c) The activity of PFK in response to various doses of F-2,6-BP activity is plotted
(black bars: with, or gray bars: without) (#p < 0.05 vs. respective gray bar).
 of Biochemistry & Cell Biology 44 (2012) 150– 157 153
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Fig. 3. The synergic effects of 5-HT and insulin on PFK activity are shown.
Homogenates of mouse muscles were assayed for PFK activity after incubation with
5-HT alone, at the concentration indicated in the ﬁgure (black bars), or with the addi-
tion  of 100 nM insulin (gray bars). The data are plotted as mean ± standard error of 6
independent experiments (n = 6). Insulin upregulates hepatic PFK activity, and acts
synergistically with 5-HT to activate the enzyme (*p < 0.05 vs. control; #p < 0.05 vs.
respective black bar).
Fig. 4. The effects of 5-HT on PFK cellular localization are described. Mouse hepatic
homogenates were incubated in the absence (control) or in the presence of 10 M
5-HT, 100 nM F-2,6BP, or both for 30 min, subjected to ultracentrifugation, and the
soluble and particulate fractions were assayed for PFK activity as described in the
Section 2. The data are plotted as mean ± standard error of 4 independent experi-
ments (n = 4), and they are represented as total PFK activity relative to control (total
PFK activity was 235 ± 31 mU/mg). Black bars: PFK activity in the soluble fractions.
Gray bars: PFK activity in the particulate fractions. 5-HT promotes an increase inW.S. Coelho et al. / The International Journal
imes indicated in Fig. 1a to measure PFK activity. The effects of 5-
T on PFK activity are time dependent until 30 min  of incubation,
nd the increased enzyme activity remains statistically signiﬁcant
ompared to control until 60 min  (p < 0.05, Student’s t-test). These
esults indicate that the effects of 5-HT on liver PFK activity require
t least 30 min  of hormonal exposure, with the maximum effect
bserved in the presence of 10 M 5-HT. Therefore, subsequent
xperiments were conducted under these conditions. When the
iver samples were exposed to 100 nM F-2,6-BP, the PFK activity
ncreased signiﬁcantly when compared to the control (p < 0.05, Stu-
ent’s t-test), as expected. The order of magnitude of this increase
s similar to the increase observed after a 5-HT stimulus. Curi-
usly, when both conditions were simultaneously added to the liver
reparations, they acted synergistically and signiﬁcantly increase
p < 0.05, Student’s t-test) the PFK activity beyond the activation
bserved with either stimulus alone (Fig. 2a). To gain further insight
n the synergic action of 5-HT and F-2,6-BP on hepatic PFK activity,
e preincubated increasing doses of 5-HT in the absence or pres-
nce of 100 nM F-2,6-BP for 30 min  and assayed enzymatic activity
Fig. 2b). We  observed an incremental increase in the positive effect
f F-2,6-BP over PFK activity that was dependent on the dose of 5-
T. The effect of 10 M 5-HT in the presence of 100 nM F-2,6-BP
ncreased PFK activity approximately 215 ± 8% compared to con-
rol, and 143 ± 8% compared to the action of F-2,6-BP alone. We
ext assayed PFK activity in the presence of increasing concentra-
ions of F-2,6-BP in the absence or presence of 10 M 5-HT. We
emonstrated that F-2,6-BP signiﬁcantly up-regulates PFK activ-
ty when the concentration is between 30 nM and 300 nM.  When
0 M 5-HT was added to the samples, we observe a synergistic
ffect on PFK activity in the presence of 30 nM and 100 nM of F-2,6-
P. Interestingly, at high concentrations of F-2,6-BP, 5-HT does not
ncrease PFK activity when compared to negative control (gray bar
ig. 2c).
F-2,6-BP is recognized as the most potent activator of PFK (Hers
nd Van Schaftingen, 1982; Uyeda et al., 1981), and its effects are
ot restricted to PFK control because this modulator also plays a
ole in regulating gluconeogenesis enzymes (Pilkis et al., 1981; Van
chaftingen and Hers, 1981). Hepatic levels of F-2,6-BP vary accord-
ng to the metabolic state of the organism, such as during fasting
r post prandial periods, which reﬂects insulinemia and glucagone-
ia. Insulin has the ability to control hepatic glycolytic ﬂux through
he control of the bi-functional enzyme PFK-2, leading to F-2,6-BP
roduction and PFK activation (Okar et al., 2001, 2004). Therefore,
e investigated PFK activity after exposure to 5-HT in the presence
f 100 nM insulin. The results obtained from these experiments
ere compared to the dose-dependent effect described previously
or the serotonergic stimulus and were also compared to the action
f 100 nM insulin alone, which acted as the positive control. These
esults reveal that when both hormones are preincubated in the
epatic tissue, the enzyme activity rises signiﬁcantly above that
bserved for the action of either hormone alone (Fig. 3) suggesting
 synergic action between 5-HT and insulin in the control of PFK
ctivity.
To understand whether the PFK activation mediated by 5-HT
nvolves the cellular redistribution of the enzyme, we  fractionated
iver TH and measured the effects of 10 M 5-HT and F-2,6-BP on
FK activity in the soluble fraction (S2) and the microsomal fraction,
hich contains most of the cytoskeleton components (El-Bacha
t al., 2003; Gomes Alves and Sola-Penna, 2003). As shown in Fig. 4,
reatment with 10 M 5-HT favors the association of PFK to the
ytoskeleton resulting in a signiﬁcant increase in PFK activity in
he particulate fraction when compared to the soluble fraction and
o the control (p < 0.05, Student’s t-test). F-2,6BP alone did not pro-
ote PFK redistribution, and both stimuli together did not induce
he effect observed with 5-HT alone, indicating that the redistri-
ution of the enzyme is not an important event to explain thethe  total enzyme activity in the particulate fraction, an effect not observed for the
F-2,6-FP stimulus alone or in the presence of 5-HT (*p < 0.05 vs. corresponding black
bar).
synergistic effect between 5-HT and F-2,6-BP in the regulation of
PFK activity.
We  next stimulated the hepatic tissue with 10 M 5-HT and
challenged it with ketanserin, a 5-HT2A receptor antagonist. The
presence of 1 M of ketanserin reverts the action of 5-HT upon
PFK activity, either alone or in the presence of F-2,6-BP. How-
ever, ketanserin could not abolish the activation of F-2,6-BP during
the activation of the enzyme (Fig. 5). Interestingly, the effect
of ketanserin in the presence of 5-HT signiﬁcantly reduced the
154 W.S. Coelho et al. / The International Journal of Biochemistry & Cell Biology 44 (2012) 150– 157
Fig. 5. The effects of 5-HT on PFK of mouse hepatic tissues is mediated through the
5-HT2A receptor. Mouse hepatic tissue homogenates were assayed for PFK activity
after incubation with 5-HT or F-2,6-BP, in the absence and presence of ketanserin
(a  5-HT2A receptor antagonist). The data are plotted as mean ± standard error of
5
a
c
e
s
i
p
T
a
a
t
a
a
T
m
t
F
e
a
a
e
c
s
Fig. 7. 5-HT induced PFK activation is dependent on PI3K. Mouse hepatic tissue
homogenates were assayed for PFK activity after incubation with 5-HT, in the
absence and presence of wortmannin (1 nM,  10 nM and 50 nM), a PI3K inhibitor. The
data are plotted as the mean ± standard error of 4 independent experiments (n = 4). independent experiments (n = 5). PFK activity is expressed as fold change over
ctivity of the control in the absence of additives. *Statistically signiﬁcant difference
ompared to the control (p < 0.05, Student’s t-test).
nzymatic activity below control levels, likely due to the intrin-
ic action of the 5-HT receptor subtype. When the skeletal muscle
soform, 5-HT2A, is activated by 5-HT, it leads to PFK activation by a
athway that is dependent on tyrosine kinases (Coelho et al., 2007).
herefore, we treated hepatic homogenates for 30 min  with 5-HT
nd genistein, a tyrosine kinase inhibitor, and then measured PFK
ctivity. Genistein treatments between 10 M and 50 M were able
o limit the action of 5-HT on PFK activity to control the level of
ctivity (Fig. 6). We  next investigated whether PI3K plays a role
s a signaling component of the 5-HT and PFK-induced activation.
o test this hypothesis, we preincubated the samples with wort-
annin, a PI3K inhibitor. The presence of wortmannin abolished
he action of 5-HT in a dose-dependent manner, where 10 nM of
ig. 6. Inhibition of tyrosine kinases with genistein abrogates the effects of 5-HT on
nzyme control. Mouse hepatic tissue homogenates were assayed for PFK activity
fter  incubation with 5-HT, in the absence and presence of genistein (1 M,  10 M
nd 50 M),  a tyrosine kinase inhibitor. The data are plotted as mean ± standard
rror of 4 independent experiments (n = 4). PFK activity is expressed as the fold
hange relative to the activity of the control in the absence of additives. *Statistically
igniﬁcant difference compared to stimulation with 5-HT (p < 0.05, Student’s t-test).PFK activity is expressed as fold change relative to the activity of the control in the
absence of additives. *Statistically signiﬁcant difference compared to stimulation by
5-HT (p < 0.05, Student’s t-test).
wortmannin partially prevented PFK activation, and concentra-
tions up to 100 nM brought the enzymatic activity to levels seen in
the control (Fig. 7). These results suggest that the positive control
exerted by 5-HT over PFK is shared with an insulin pathway. How-
ever, the synergic effect observed by the stimulus of both hormones
together suggests an additive pathway or an alternative mechanism
for the activation of the enzyme.
The 5-HT2A receptor subtype is able to induce the activation a
PLC. Therefore, we challenged the hepatic tissue in the presence
of 10 M U-73122, a PLC inhibitor, and assayed for PFK activity.
These experiments revealed that the action of 5-HT is dependent on
PLC activation because the inhibition of this phospholipid reduced
the ability of 5-HT to promote enzyme activity (Fig. 8). To further
characterize this pathway, we pre treated the tissue preparations
with the phorbol ester, PMA, for 30 min, which mimics the action of
diacylglycerol (DAG), to activate protein kinase C (PKC). PMA  was
Fig. 8. Inhibition of PLC prevents 5-HT-mediated upregulation of PFK activity.
Mouse hepatic tissue samples were incubated with 5-HT in the absence or pres-
ence of 10 M U-73122, a PLC inhibitor, and the activity of PFK was measured as
described in the Section 2. The data are plotted as the mean ± standard error of 4
independent experiments (n = 4). *Statistically signiﬁcant difference compared to
stimulation with 5-HT (p < 0.05, Student’s t-test).
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Fig. 9. The phorbol ester mimics, serotonin and serotonin Fru-2,6-BP, show synergistic effects upon the control of PFK activity. Mouse liver samples were pre-incubated for
30  min  with PMA  alone (white dashed bars), or in the presence of 100 nM F-2,6-BP (gray dashed bars), at the concentrations indicated in the ﬁgure. PFK activity was  measured
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black bar) (p < 0.05, Student’s t-test). #Statistically signiﬁcant differences compared
dded to the samples in the concentrations indicated in Fig. 9, in
he presence or absence of 100 nM F-2,6-BP. We  demonstrated that
MA  alone is able to upregulate PFK activity in a dose-dependent
anner that is similar to the effect observed with the treatment of
-HT. Additionally, the presence of PMA  acts synergistically with
-2,6-BP to activate PFK and depends on lower concentrations of
MA  compared to the action of PMA  alone to promote PFK activity.
Together, these results indicate that 5-HT is able to activate
epatic PFK through at least two independent signaling pathways.
-HT2A is coupled to the activation of PI3K and PLC, which leads
o PKC recruitment. Cellular redistribution of PFK is an important
echanism that regulates the enzyme after a 5-HT stimulus and
cts in a synergistic manner with insulin.
. Discussion
Serotonergic nerve ﬁbers have previously been shown to be
ocalized to the tunica media on branches of hepatic artery and
ortal vein, as well as in bile ducts and the connective tissue of the
nterlobular septa (el-Salhy et al., 1993). Some authors have pro-
ided evidence for 5-HT-mediated liver regeneration (Hsu, 1995;
hoi et al., 2002) where it acts as a neurotransmitter and an
ndocrine hormone (Ruddell et al., 2006). Despite these observa-
ions, the importance of serotonergic innervations to the human
iver is not completely understood, and very few studies have inves-
igated the effects of serotonin in the control of glucose metabolism.
hysiological studies conducted by Moore and colleagues (Moore
t al., 2004a,b, 2005a,b) revealed an augmented glucose uptake
fter 5-HT infusion in the portal vein. Here, we describe for the
rst time, the role of 5-HT in regulating the glycolytic enzyme PFK
n mice hepatic tissue.
Preincubation of liver samples with 10 M 5-HT after 30 min
f hormone exposure promotes a dose and time-dependent acti-
ation of PFK that is signiﬁcantly increased compared to control.
he activation promoted by 5-HT is potentiated by the presence of
-2,6-BP or insulin. Insulin is known to increase liver F-2,6-BP pro-
uction through its ability to upregulate the bi-functional enzyme
FK-2 (Hamer and Dickson, 1990). These observations suggest that
he synergistic effect between 5-HT and insulin is due to increasedndent experiments (n = 6). *Statistically signiﬁcant differences compared to control
ntrol (black bar) and to 10 M 5-HT (white bar) (p < 0.05, Student’s t-test).
levels of F-2,6-BP in hepatic tissue. F-2,6-BP is the most potent
allosteric modulator of PFK and plays a crucial role in the con-
trol of hepatic glucose metabolism (Okar et al., 2004; Choi et al.,
2002; Wu et al., 2006). Additionally, -metil-5-HT, a 5-HT1/5-HT2
receptor agonist, stimulates glycogen synthesis and acts synergisti-
cally with the most effective insulin concentration (Hampson et al.,
2007). In fact, an increase in hepatic glycolysis promoted by PFK-2
or over expression of glucokinase reduces obesity (Wu et al., 2005),
glycemia in diabetes (Choi et al., 2002), and the hepatic production
of glucose, which suppresses hepatic insulin resistance in type 2
diabetes (Wu et al., 2002). Similarly, treatment with 5-HT selective
reuptake inhibitors improves glucose tolerance in type 2 diabetes
(Pestell et al., 1989).
The interaction between PFK and f-actin is promoted by 5-
HT and is an important mechanism in the upregulation of the
enzyme activity, and this observation is consistent with previous
work (Coelho et al., 2007). In addition, many investigators have
shown that the ability of PFK to associate with f-actin after a vari-
ety of stimuli is a crucial event that precedes enzyme activation
(Zancan and Sola-Penna, 2005a,b; Gomes Alves and Sola-Penna,
2003; Assouline-Cohen et al., 1998; Silva et al., 2004; Kuo et al.,
1986; Leite et al., 2007; Marinho-Carvalho et al., 2006, 2009; Meira
et al., 2005; Real-Hohn et al., 2010; Sola-Penna et al., 2010; Spitz
et al., 2009). However, F-2,6-BP did not increase PFK activity in the
f-actin enriched fraction, nor did it potentiate 5-HT effect, suggest-
ing that the synergic action of 5-HT and F-2,6-BP likely involves
the enzyme redistribution stimulated by 5-HT and the allosteric
regulation promoted by F-2,6-BP.
The reported effects of 5-HT on PFK control in hepatic tis-
sue occur after recruitment of the 5-HT2A receptor. Ketanserin
abrogates the 5-HT-induced PFK activation in the skeletal mus-
cle (Coelho et al., 2007). The participation of this receptor isotype
has been previously described as important for 5-HT to promote
liver wound healing after injury (Ruddell et al., 2008). Furthermore,
ketanserin is a potent inhibitor of this process (Papadimas et al.,
2006). Moreover, the ability of 5-HT to control hepatic blood ﬂow
and vascular tonus is reduced after the administration of various
5-HT2A antagonists (Ruddell et al., 2008). Treatment of liver sam-
ples with genistein and wortmannin, a tyrosine kinase and a PI3K
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nhibitor, respectively, was able to prevent the 5-HT effect, sug-
esting a role for an insulin mutual pathway that is distinct from
he effects of 5-HT in PFK control in skeletal muscle (Coelho et al.,
007). Furthermore, the inhibition of PLC and PKC also abolished
he 5-HT effect, and the presence of PMA  was able to mimic  the
-HT effect alone; the inhibition also resulted in a synergic activa-
ion of PFK when the samples were preincubated simultaneously
ith PMA  and F-2,6-BP. Together, these results suggest that 5-HT-
ediated regulation of PFK activity is dependent on a PLC–PKC and
 PI3K tyrosine kinase pathway. Furthermore, this role is consistent
ith the ﬁndings of many studies that have correlated the role of
hese pathway components with the activation of 5-HT2A receptor
Coelho et al., 2007; McKune and Watts, 2001; Ogden et al., 2006;
u et al., 2008; Honda et al., 1998; Tang and Tan, 2003; Guillet-
eniau et al., 1997; Quinn et al., 2002; Banes et al., 2005; Liu and
anburg, 2006).
Additional experiments are required to characterize the other
athway elements that may  participate in the 5-HT-mediated con-
rol of glycolysis. CaMK may  be an interesting candidate for future
nvestigation because previous studies have presented evidence of
lycolytic enzyme control being modulated by this signaling pro-
ein (Mieskes et al., 1987). The liver presents the extraordinary
bility to recover from injury (Mabuchi et al., 2004), and many
uestions related to this topic are yet to be investigated. Although
here is a consensus in the literature that 5-HT plays an impor-
ant role in wound healing processes, growth factor expression,
ell proliferation and blood ﬂow regulation (Ruddell et al., 2008),
he correlation between the control of hepatic glycolysis and these
rocesses requires more investigation.
In conclusion, we are the ﬁrst to provide evidence that hep-
tic PFK control is mediated by 5-HT in an insulin synergic manner
equiring the activation of the PI3K and PLC–PKC pathways and
hat changes in PFK cellular localization is a mechanism of PFK
ctivation.
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